- Primary DLBCL lymphoma in sacral bone - case report2023 | First Faculty of Medicine, Third Faculty of Medicine
- EBV plus diffuse large B-cell lymphoma arising within atrial myxoma. An example of a distinct primary cardiac EBV plus DLBCL of immunocompetent patients2012 | First Faculty of Medicine
- What do we miss and get if we replace bone marrow biopsy in DLBCL with staging PET/CTPublication without faculty affiliation
- Stanovení diferenciální exprese dlouhých nekódujících RNA z plasmy pacientů s difúzním velkobuněčným B-lymfomem (DLBCL)Publication without faculty affiliation
- Assessing Bone Marrow Involvement in DLBCL: Comparison of FDG PET and Bone Marrow BiopsyPublication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: CRAD00IN2301Publication without faculty affiliation
- End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Dimethyl fumarate induces ferroptosis and impairs NF-kappa B/STAT3 signaling in DLBCL2021 | First Faculty of Medicine
- Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20(+) Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma2012 | First Faculty of Medicine
- Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL2017 | First Faculty of Medicine
- Diffuse large B cell lymphomas (DLBCL):analysis of the heterogeneous group by means of immunohistochemistry, PCR and FISHPublication without faculty affiliation
- Diffuse large B cell lymphomas (DLBCL) analysis of the heterogeneous group by means of immunohistochemistry, PCR and FISHPublication without faculty affiliation
- Experimental therapy of B-cell Non-Hodgkin's lymphonasPublication without faculty affiliation
- Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options2022 | First Faculty of Medicine
- Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment2021 | First Faculty of Medicine
- Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies2021 | First Faculty of Medicine
- BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis2021 | First Faculty of Medicine
- Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab2013 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis2023 | First Faculty of Medicine
- Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL2019 | First Faculty of Medicine
- Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study2020 | First Faculty of Medicine
- Rituximab signifikantně zlepšuje osud mladých nemocných s difúzním velkobuněčným lymfomem (DLBCL) a špatným prognostickým rizikem dle IPI +1Publication without faculty affiliation
- Rituximab signifikntně zlepšuje osud mladých nemocných s difúzním velkobuněčným lymfomem (DLBCL) a špatným prognostickým rizikem dle IPIPublication without faculty affiliation
- Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma2020 | First Faculty of Medicine
- Časný restaging pomocí pozitronové emisní tomografie (PET) u nemocných s difúzním velkobuněčným lymfomem (DLBCL) má signifikantní prognostický význam.Publication without faculty affiliation
- PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design2022 | First Faculty of Medicine
- ABCL-022 Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase Ib, Open-Label, Randomized Study of Tafasitamab +- Lenalidomide + R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaPublication without faculty affiliation